SG11201809127PA - Crystalline polymorph of 15b-hydroxy-osaterone acetate - Google Patents

Crystalline polymorph of 15b-hydroxy-osaterone acetate

Info

Publication number
SG11201809127PA
SG11201809127PA SG11201809127PA SG11201809127PA SG11201809127PA SG 11201809127P A SG11201809127P A SG 11201809127PA SG 11201809127P A SG11201809127P A SG 11201809127PA SG 11201809127P A SG11201809127P A SG 11201809127PA SG 11201809127P A SG11201809127P A SG 11201809127PA
Authority
SG
Singapore
Prior art keywords
hydroxy
osaterone acetate
polymorphic form
crystalline polymorph
crystalline polymorphic
Prior art date
Application number
SG11201809127PA
Other languages
English (en)
Inventor
Takayoshi Nakagawa
Hiroyuki Hayashi
Koichi Miyazaki
Shigeki Iwashita
Original Assignee
Aska Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aska Pharmaceutical Co Ltd filed Critical Aska Pharmaceutical Co Ltd
Publication of SG11201809127PA publication Critical patent/SG11201809127PA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J73/00Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • C07J73/001Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
    • C07J73/003Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by oxygen as hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28Antiandrogens
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J73/00Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/08Antiseborrheics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11201809127PA 2016-05-11 2017-05-10 Crystalline polymorph of 15b-hydroxy-osaterone acetate SG11201809127PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016095382 2016-05-11
PCT/JP2017/017619 WO2017195804A1 (ja) 2016-05-11 2017-05-10 15β-ヒドロキシ-酢酸オサテロンの結晶多形

Publications (1)

Publication Number Publication Date
SG11201809127PA true SG11201809127PA (en) 2018-11-29

Family

ID=60267316

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201809127PA SG11201809127PA (en) 2016-05-11 2017-05-10 Crystalline polymorph of 15b-hydroxy-osaterone acetate

Country Status (15)

Country Link
US (1) US10508130B2 (ru)
EP (1) EP3456729B1 (ru)
JP (2) JP7210278B2 (ru)
KR (1) KR102383617B1 (ru)
CN (1) CN109153701B (ru)
AU (1) AU2017264187B2 (ru)
BR (1) BR112018071950A2 (ru)
CA (1) CA3021179A1 (ru)
EA (1) EA034965B1 (ru)
ES (1) ES2829578T3 (ru)
MX (1) MX2018013786A (ru)
MY (1) MY195203A (ru)
PH (1) PH12018502365A1 (ru)
SG (1) SG11201809127PA (ru)
WO (1) WO2017195804A1 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2829578T3 (es) * 2016-05-11 2021-06-01 Aska Pharm Co Ltd Polimorfo cristalino de acetato de 15ß-hidroxi-osaterona
AU2020358203A1 (en) * 2019-10-02 2022-03-31 Aska Pharmaceutical Co., Ltd. Dysuria-alleviating agent
EP4265258A1 (en) * 2020-12-18 2023-10-25 ASKA Pharmaceutical Co., Ltd. Solid formulation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3663668D1 (de) 1985-03-07 1989-07-06 Teikoku Hormone Mfg Co Ltd 2-oxa- or aza-pregnane compounds
JPS61204199A (ja) * 1985-03-07 1986-09-10 Teikoku Hormone Mfg Co Ltd 2−アザプレグナン化合物
JPS61204198A (ja) * 1985-03-07 1986-09-10 Teikoku Hormone Mfg Co Ltd 2−オキサプレグナン化合物
JPS62195398A (ja) * 1986-02-21 1987-08-28 Teikoku Hormone Mfg Co Ltd 黄体ホルモン剤
JP2591640B2 (ja) * 1988-02-04 1997-03-19 帝国臓器製薬株式会社 新規な2−オキサプレグナン化合物
JP2980992B2 (ja) * 1990-12-28 1999-11-22 帝国臓器製薬株式会社 6−ハロゲノ−2−オキサプレグナ−4,6−ジエン−3−オン化合物の製造方法
JP2591640Y2 (ja) 1993-05-13 1999-03-10 株式会社吉野工業所 液体収納袋
US7689305B2 (en) 2004-03-26 2010-03-30 Harman International Industries, Incorporated System for audio-related device communication
JP6192228B2 (ja) 2014-05-23 2017-09-06 本田技研工業株式会社 物体認識装置
ES2829578T3 (es) 2016-05-11 2021-06-01 Aska Pharm Co Ltd Polimorfo cristalino de acetato de 15ß-hidroxi-osaterona

Also Published As

Publication number Publication date
EA201892566A1 (ru) 2019-04-30
EP3456729A1 (en) 2019-03-20
JP7241807B2 (ja) 2023-03-17
KR102383617B1 (ko) 2022-04-05
CA3021179A1 (en) 2017-11-16
AU2017264187A1 (en) 2018-11-15
WO2017195804A1 (ja) 2017-11-16
JPWO2017195804A1 (ja) 2019-03-07
BR112018071950A2 (pt) 2019-02-05
US20190127417A1 (en) 2019-05-02
PH12018502365A1 (en) 2019-09-09
JP2021121645A (ja) 2021-08-26
JP7210278B2 (ja) 2023-01-23
EA034965B1 (ru) 2020-04-13
KR20190004787A (ko) 2019-01-14
MX2018013786A (es) 2019-03-28
EP3456729A4 (en) 2019-05-22
CN109153701A (zh) 2019-01-04
US10508130B2 (en) 2019-12-17
CN109153701B (zh) 2021-02-02
MY195203A (en) 2023-01-11
EP3456729B1 (en) 2020-09-02
ES2829578T3 (es) 2021-06-01
AU2017264187B2 (en) 2021-02-18

Similar Documents

Publication Publication Date Title
MY186531A (en) Crystals
WO2017136727A3 (en) Inhibitors of receptor-interacting protein kinase 1
MX2018006443A (es) Compuestos que inhiben eif4a y métodos relacionados a los mismos.
SG11201809127PA (en) Crystalline polymorph of 15b-hydroxy-osaterone acetate
MY173410A (en) Stable crystal form of tipiracil hydrochloride and crystallization method for the same
MX2017012568A (es) Cristal del compuesto alquinil benceno 3,5-disustituido.
WO2015077058A3 (en) Compositions and methods for selecting a treatment for b-cell neoplasias
NZ757221A (en) Crystalline forms of diazabicyclooctane derivative and production process thereof
MY189912A (en) Substituted xanthines and methods of use thereof
WO2014144539A3 (en) Dynamic urea bonds for reversible and self-healing polymers
WO2014136282A8 (en) Crystalline form having specific crystal habit and pharmaceutical composition containing this crystalline form as active ingredient
MX2016016426A (es) Protector desmontable para artículo protector para la cabeza.
PH12020550133A1 (en) Crystal forms of immunomodulators
PH12019502588A1 (en) Crystal form c of sanzuohuangcaotong, preparation method and use thereof
WO2012052479A3 (en) Brimonidine gel compositions and methods of use
EP3342837A4 (en) ADHESIVE AND ADHESIVE FILM COMPOSITION, ENERGY STORAGE DEVICE COMPOSITION, ENERGY STORAGE DEVICE ELECTRODE PASTE, ENERGY STORAGE DEVICE ELECTRODE, PROTECTIVE FILM PASTE, AND ENERGY STORAGE DEVICE
WO2014164648A4 (en) Solid state forms of a quinazoline derivative and its use as a braf inhibitor
PH12015502122A1 (en) Sovaprevir polymorphs and methods of manufacturing thereof
EP3418277A4 (en) Substituted amino six-membered nitric heterocyclic ring compound and preparation and use thereof
MX2020007315A (es) Cristal.
WO2015017378A3 (en) Novel copper-cysteamine and methods of use
MX2018013764A (es) Cristal de derivado de quinolina.
EP2968407A4 (en) Individualized high purity colon carcinoma stem cells, methods and use of the same
NZ742695A (en) Solid forms of substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds
EP3774844A4 (en) USEFUL CRYSTALLINE DIPEPTIDES IN THE SYNTHESIS OF ELAMIPRETIDE